EGF-induced Expression of Fused Toes Homolog (FTS) Facilitates Epithelial-mesenchymal Transition and Promotes Cell Migration in ME180 Cervical Cancer Cells

Overview

Journal Cancer Lett

Specialty Oncology

Date 2014 Jun 28

PMID 24971934

Citations 17

Authors

Sridhar Muthusami

D S Prabakaran

Jae-Ran Yu

Woo-Yoon Park

Affiliations

Soon will be listed here.

Abstract

The role of Fused Toes Homolog (FTS) in epidermal growth factor (EGF) induced epithelial-mesenchymal transition (EMT) in cervical cancer cells was studied. EGF treatment induced the change of EMT markers and increased cell migration. EGF treatment also increased phosphorylated EGFR and ERK and nuclear level of ATF-2. The binding of ATF-2 to the promoter region of FTS was evidenced after EGF treatment. Pretreatment with PD98059 and gefitinib prevented EGF-induced FTS expression. FTS silencing reduced EMT and cell migration by EGF treatment. These results demonstrate a novel function for FTS in EGF-mediated EMT process.

Citing Articles

Plumbagin as a preferential lead molecule to combat EGFR-driven matrix abundance and migration of cervical carcinoma cells.

Krishnamoorthy S, Sabanayagam R, Periyasamy L, Muruganantham B, Muthusami S Med Oncol. 2024; 41(4):89.

PMID: 38520625 DOI: 10.1007/s12032-024-02332-6.

A comparative analysis of phyto-components on EGFR binding, viability, and migration in HPV positive ME180 and HPV negative C33A cervical cancer cells.

Sabanayagam R, Krishnamoorthy S, Anbuselvam M, Muruganantham B, Muthusami S Med Oncol. 2023; 40(12):357.

PMID: 37964051 DOI: 10.1007/s12032-023-02223-2.

EGCG attenuate EGF triggered matrix abundance and migration in HPV positive and HPV negative cervical cancer cells.

Sabanayagam R, Krishnamoorthy S, Gnanagurusamy J, Muruganatham B, Muthusami S Med Oncol. 2023; 40(9):261.

PMID: 37544940 DOI: 10.1007/s12032-023-02135-1.

Plumbagin binds to epidermal growth factor receptor and mitigate the effects of epidermal growth factor micro-environment in PANC-1 cells.

Periyasamy L, Murugantham B, Muthusami S Med Oncol. 2023; 40(7):184.

PMID: 37209241 DOI: 10.1007/s12032-023-02048-z.

AKTIP loss is enriched in ERα-positive breast cancer for tumorigenesis and confers endocrine resistance.

Ng A, Zhang S, Mak V, Zhou Y, Yuen Y, Sharma R Cell Rep. 2022; 41(11):111821.

PMID: 36516775 PMC: 9837615. DOI: 10.1016/j.celrep.2022.111821.